UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.460

Sortiert nach

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1380-1390

2019

Link zum Volltext

Verfügbarkeit prüfen

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Gynecologic oncology reports, 2023-12, Vol.50, p.101311, Article 101311

Rose, Peter G

2023

Link zum Volltext

Verfügbarkeit prüfen

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Journal of clinical oncology, 2015-07, Vol.33 (19), p.2136-2142

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of Surgery in Ovarian Carcinoma

Journal of clinical oncology, 2007-07, Vol.25 (20), p.2873-2883

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-08, Vol.25 (24), p.3621-3627

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2259-2265

2011

Link zum Volltext

Verfügbarkeit prüfen

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2008-01, Vol.26 (1), p.83-89

2008

Link zum Volltext

Verfügbarkeit prüfen

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Gynecologic oncology, 2008-06, Vol.109 (3), p.329-334

2008

Link zum Volltext

Verfügbarkeit prüfen

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Gynecologic oncology, 2018-08, Vol.150 (2), p.247-252

2018

Link zum Volltext

Verfügbarkeit prüfen

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation

Gynecologic oncology, 2014-11, Vol.135 (2), p.208-212

2014

Link zum Volltext

Verfügbarkeit prüfen

Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center

Gynecologic oncology, 2013-07, Vol.130 (1), p.121-126

2013

Link zum Volltext

Verfügbarkeit prüfen

Fertility-Sparing Surgery for Early-Stage Cervical Cancer: A Systematic Review of the Literature

Journal of minimally invasive gynecology, 2021-03, Vol.28 (3), p.513-526.e1

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2727-2731

2010

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

The oncologist (Dayton, Ohio), 2005-03, Vol.10 (3), p.205-214

Rose, Peter G.

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

Gynecologic oncology, 2015-02, Vol.136 (2), p.240-245

2015

Link zum Volltext

Verfügbarkeit prüfen

Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?

Gynecologic oncology, 2012-05, Vol.125 (2), p.285-286

Rose, Peter G

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2804-2810

2007

Link zum Volltext

Verfügbarkeit prüfen

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Gynecologic oncology, 2008-06, Vol.109 (3), p.323-328

2008

Link zum Volltext

Verfügbarkeit prüfen

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

NPJ precision oncology, 2021-12, Vol.5 (1), p.101-11, Article 101

2021

Link zum Volltext

Verfügbarkeit prüfen

Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes

International journal of gynecological cancer, 2019-09, Vol.29 (7), p.1126-1133

2019

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Gynecologic oncology, 2012-11, Vol.127 (2), p.345-350

2012

Link zum Volltext

Verfügbarkeit prüfen

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

The New England journal of medicine, 2004-12, Vol.351 (24), p.2489-2497

2004

Link zum Volltext

Verfügbarkeit prüfen

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

Frontiers in oncology, 2024, Vol.14, p.1291090-1291090

2024

Link zum Volltext

Verfügbarkeit prüfen

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Journal of ovarian research, 2023-06, Vol.16 (1), p.122-122, Article 122

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Gynecologic oncology, 2011-05, Vol.121 (2), p.303-308

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.460

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.334)
Mit Volltextzugriff
(1.287)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Role of Surgery in Ovarian Carcinoma

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation

Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center

Fertility-Sparing Surgery for Early-Stage Cervical Cancer: A Systematic Review of the Literature

Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Suchergebnisse filtern